{"id":"NCT01695239","sponsor":"Eli Lilly and Company","briefTitle":"A Study of Ixekizumab in Participants With Active Psoriatic Arthritis","officialTitle":"A Multicenter, Randomized, Double-Blind, Active and Placebo-Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients With Active Psoriatic Arthritis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-12","primaryCompletion":"2014-12","completion":"2017-09","firstPosted":"2012-09-27","resultsPosted":"2016-10-27","lastUpdate":"2019-01-08"},"enrollment":417,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Psoriasis, Arthritic"],"interventions":[{"type":"DRUG","name":"Ixekizumab","otherNames":["LY2439821"]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Adalimumab","otherNames":[]}],"arms":[{"label":"Ixekizumab Q2W","type":"EXPERIMENTAL"},{"label":"Ixekizumab Q4W","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Adalimumab Q2W","type":"ACTIVE_COMPARATOR"}],"summary":"This study will assess the safety and efficacy of ixekizumab (LY2439821) compared to placebo in participants with active psoriatic arthritis.","primaryOutcome":{"measure":"Percentage of Participants Achieving American College of Rheumatology 20 (ACR20) Response at Week 24 (Efficacy of Ixekizumab in Participants With Active Psoriatic Arthritis. Measure: American College of Rheumatology 20 Index [ACR20])","timeFrame":"Week 24","effectByArm":[{"arm":"Placebo","deltaMin":30.2,"sd":null},{"arm":"Adalimumab Q2W","deltaMin":57.4,"sd":null},{"arm":"Ixekizumab Q4W","deltaMin":57.9,"sd":null},{"arm":"Ixekizumab Q2W","deltaMin":62.1,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"},{"comp":"OG000 vs OG002","p":"<0.001"},{"comp":"OG000 vs OG003","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":8},"locations":{"siteCount":116,"countries":["United States","Belgium","Bulgaria","Canada","Czechia","Estonia","France","Japan","Mexico","Netherlands","Poland","Russia","Spain","Ukraine","United Kingdom"]},"refs":{"pmids":["40014255","38955921","38814433","37858007","36171019","35397092","35393269","33499913","32792421","32031665","31964419","31154634","30886974","30696483","29945203","29299340","29247148","27553214"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":106},"commonTop":["Viral upper respiratory tract infection","Upper respiratory tract infection","Injection site reaction","Bronchitis","Injection site erythema"]}}